Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
This strategic collaboration with atai Life Sciences will focus on the creation of small molecule therapies by building on the mechanism of action of psychedelic and related compounds.
Lead Product(s): Psychedelics-based Therapeutic
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: ATAI Life Sciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 27, 2022
Details:
Champignon Brands has selected Toronto-based Dalriada Drug Discovery Inc.to advance its new chemical entity IP portfolio as it pertains to ketamine and psilocybin/psilicin molecular scaffolds.
Lead Product(s): Psilocybine,Cannabidiol
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Champignon
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 08, 2020